Discover 1,243 paid clinical trials in Nashville, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Nashville offers many research opportunities for conditions such as diabetes, cardiovascular disease, and arthritis, giving participants access to innovative treatments and cutting-edge medical care. The city’s leading healthcare institutions are actively recruiting healthy volunteers for paid research studies, as well as individuals seeking trials for specific health concerns.
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
for
Acne
Location: Smyrna TN, Bowling Green KY, Decatur GA,
Sponsor: Sanofi Pasteur, a Sanofi Company
Sex: All
Age: 18 - 45
Code: NCT06316297
Phase 1, Phase 2, Recruiting
Featured
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
for
Immunoglobulin Light Chain (AL) Amyloidosis
Location: Nashville TN, Charlotte NC, Winston-Salem NC,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT06158854
Phase 1, Phase 2, Recruiting
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
for
Idiopathic Pulmonary Fibrosis
Location: Hendersonville TN, Rock Hill SC, Dothan AL, Hannibal MO,
Sponsor: Chiesi Farmaceutici S.p.A.
Sex: All
Age: 40+
Code: NCT07516951
Phase 2, Recruiting
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
for
Liver Diseases, Alcoholic
Location: Hermitage TN, Atlanta GA, Indianapolis IN,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18 - 70
Code: NCT06613698
Phase 2, Recruiting
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
for
HIV Infections
Location: Nashville TN, Philadelphia PA, Boston MA,
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)